natgillin/translations-raw huggingface dataset:
f. Plus baggrundsbehandlingsplan med emtricitabin 200 mg og tenofovir DF 300 mg i fastdosiskombination.
f Plus background regimen of emtricitabine 200 mg and tenofovir DF 300 mg fixed-dose combination.
Samtidig administration af EVOTAZ og tenofoviralafenamid 25 mg til behandling af HBVinfektion frarådes
Co-administration of EVOTAZ and tenofovir alafenamide 25 mg for treatment of HBV infection is not recommended
EVOTAZ's antiretrovirale effekt skyldes indholdsstoffet atazanavir.
The antiretroviral effect of EVOTAZ is due to the atazanavir component.
Pink, oval, bikonveks, filmovertrukket tablet med omtrentlig dimension på 19 mm x 10,4 mm og præget med ”3641” på den ene side og glat på den anden side.
Pink, oval, biconvex, film-coated tablet of approximate dimensions of 19 mm x 10.4 mm, debossed with "3641" on one side and plain on the other side.
LÆGEMIDDELFORM OG INDHOLD (PAKNINGSSTØRRELSE) 30 filmovertrukne tabletter.
PHARMACEUTICAL FORM AND CONTENTS 30 film-coated tablets.
Der er rapporteret alvorligt hududslæt, herunder Stevens-Johnsons syndrom, hos patienter, der tager EVOTAZ.
Serious skin rash, including Stevens-Johnson syndrome, may develop in patients taking EVOTAZ.
Hvis du bemærker et eller flere af disse symptomer, skal du fortælle det til lægen.
If you notice any of these symptoms please inform your doctor.
Atazanavir-koncentrationen påvirkes ikke signifikant.
Concentrations of atazanavir were not significantly affected.
Atazanavir + cobicistat + emtricitabin og tenofovir DF i fastdosiskombination var non-inferiøre med hensyn til at opnå hiv-1-RNA <50 kopier/ml, sammenlignet med atazanavir + ritonavir + emtricitabin og tenofovir DF i fastdosiskombination.
Atazanavir with cobicistat and emtricitabine and tenofovir DF fixed-dose combination was non-inferior in achieving HIV-1 RNA <50 copies/ml when compared to atazanavir with ritonavir and emtricitabine and tenofovir DF fixed-dose combination.
Immunreaktiveringssyndrom og autoimmune lidelser
Immune reactivation syndrome and autoimmune disorders
Nukleosid/nukleotid reverse transkriptasehæmmere (NRTI'er)
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)
En opdateret RMP skal fremsendes: på anmodning fra Det Europæiske Lægemiddelagentur når risikostyringssystemet ændres, særlig som følge af, at der er modtaget nye oplysninger, der kan medføre en væsentlig ændring i benefit/risk-forholdet, eller som følge af, at en vigtig milepæl (lægemiddelovervågning eller risikominimering) er nået.
Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
Samtidig administration af EVOTAZ kan potentielt medføre alvorlige og/eller livstruende bivirkninger.
Co-administration with EVOTAZ has the potential to produce serious and/or life-threatening adverse reactions.
Selvom det ikke er undersøgt, er der risiko for en øget pravastatineller fluvastatin-eksponering ved administration sammen med proteasehæmmere.
Although not studied, there is a potential for an increase in pravastatin or fluvastatin exposure when co-administered with protease inhibitors.
Samtidig administration af EVOTAZ og ticagrelor kan øge koncentrationen af antikoagulanten.
Co- administration of EVOTAZ and ticagrelor may increase concentrations of the anticoagulant.
Administration af en enkeltdosis EVOTAZ med et fedtrigt måltid (1.038 kcal, 59 g fedt, 37 g protein) medførte en 14% reduktion i atazanavir Cmax men ingen ændringer i atazanavir AUC eller cobicistat-eksponering (Cmax, AUC) i forhold til fastende tilstand.
Administration of a single dose of EVOTAZ with a high fat meal (1,038 kcal, 59 g fat, 37 g protein) resulted in a 14% reduction in atazanavir Cmax with no change in atazanavir AUC or cobicistat exposures (Cmax, AUC) relative to the fasting state.
Cobicistats hæmning af CYP3A-medieret metabolisme øger den systemiske eksponering over for CYP3A-substrater, såsom atazanavir, som har begrænset biotilgængelighed og en kort halveringstid på grund af den CYP3A-afhængige metabolisme.
Inhibition of CYP3A-mediated metabolism by cobicistat enhances the systemic exposure of CYP3A substrates, such as atazanavir, where bioavailability is limited and half-life is shortened by CYP3A-dependent metabolism.
Forsigtighed anbefales.
Caution is warranted.
Klinisk monitorering og laboratoriemonitorering for hyperbilirubinæmi anbefales.
Clinical and laboratory monitoring for hyperbilirubinaemia is recommended.
Forsøgspersoner, der udviste signifikante anormaliteter i leverfunktionstests, havde generelt abnorme baseline transaminase-værdier (ASAT eller ALAT), underliggende kronisk eller akut hepatitis B eller -C-infektion, fik samtidig hepatotoksiske lægemidler (f.eks. isoniazid) eller havde alkoholisme eller alkoholmisbrug i anamnesen.
Subjects with significant liver function test abnormalities generally had abnormal baseline transaminases (AST or ALT), underlying chronic or acute hepatitis B or C co-infection, concomitant hepatotoxic medications (e.g., isoniazid), or a medical history of alcoholism or alcohol abuse.
EVOTAZ er en fastdosiskombination af det antivirale lægemiddel atazanavir boostet med den farmakokinetiske forstærker cobicistat.
EVOTAZ is a fixed-dose combination of the antiviral drug atazanavir boosted by the pharmacokinetic enhancer cobicistat.
Samtidig administration af neuroleptika og EVOTAZ kan medføre øgede plasmakoncentrationer af neuroleptika.
Co-administration of neuroleptics with EVOTAZ may result in increased plasma concentrations of neuroleptics.
Brug af anden medicin sammen med EVOTAZ
Other medicines and EVOTAZ
Samtidig administration af EVOTAZ og ticagrelor er kontraindiceret.
Concomitant administration of EVOTAZ with ticagrelor is contraindicated.
EVOTAZ frarådes til samtidig administration med efavirenz.
EVOTAZ is not recommended for co-administration with efavirenz.
Anvendelse af EVOTAZ er kontraindiceret hos patienter med moderat til svært nedsat leverfunktion.
The use of EVOTAZ is contraindicated in patients with moderate to severe hepatic impairment.
Moderat til svært nedsat leverfunktion.
Moderate to severe hepatic impairment.
Hvert enkelt lægemiddelstof påvirkede venstre ventrikulær kontraktilitet og PR-forlængelse ved koncentrationer mindst 35 gange højere end frie atazanavir- og cobicistat-koncentrationer ved den anbefalede humane dosis (RHD) Cmax.
Each single agent produced effects on left ventricular contractility and PR prolongation at concentrations at least 35-fold higher than the free atazanavir and cobicistat concentrations at the recommended human dose (RHD) Cmax.
Virologisk svigtc
Virologic success
Der er observeret øgede plasmakoncentrationer af lægemidler, som metaboliseres af CYP3A (herunder atazanavir) ved samtidig administration af cobicistat.
Increased plasma concentrations of medicinal products that are metabolised by CYP3A (including atazanavir) are observed on co-administration with cobicistat.
Simvastatin og lovastatin metaboliseres i høj grad via CYP3A4 og samtidig administration med EVOTAZ kan medføre øgede koncentrationer.
Simvastatin and lovastatin are highly dependent on CYP3A4 for their metabolism and co-administration with EVOTAZ may result in increased concentrations.
Kortikosteroider, som er mindre afhængige af CYP3Ametabolisering, f.eks. nasal eller inhaleret beclometason, bør overvejes, navnlig ved langvarig brug.
Alternative corticosteroids which are less dependent on CYP3A metabolism, e.g. beclomethasone for intranasal or inhalational use, should be considered, particularly for long term use.
Kombinationen af pimozid, quetiapin eller lurasidon og EVOTAZ er kontraindiceret (se pkt.
The combination of pimozide, quetiapine or lurasidone and EVOTAZ is contraindicated (see section 4.3).
Atazanavir, doseret 1 time efter ddI+d4T (fastende) Atazanavir AUC ↔3% (↓36%
Atazanavir, dosed 1 hr after ddI+d4T (fasted) Atazanavir AUC ↔3% (↓36%
Der bør udvises forsigtighed, og monitorering af terapeutiske koncentrationer for disse lægemidler anbefales ved samtidig anvendelse med EVOTAZ.
Caution is warranted and therapeutic concentration monitoring of these medicinal products is recommended if they are used concomitantly with EVOTAZ.
Rifabutin AUC ↑48% (↑19% Rifabutin Cmax ↑149% (↑103% Rifabutin Cmin ↑40% (↑5% ↑87%)* 25-O-desacetyl-rifabutin AUC 25-O-desacetyl-rifabutin Cmax 25-O-desacetyl-rifabutin Cmin *Sammenlignet med rifabutin 150 mg 1 gang dagligt.
Rifabutin AUC ↑48% (↑19% Rifabutin Cmax ↑149% (↑103% Rifabutin Cmin ↑40% (↑5% 25-O-desacetyl-rifabutin AUC 25-O-desacetyl-rifabutin Cmax 25-O-desacetyl-rifabutin Cmin *When compared to rifabutin 150 mg once daily alone.
Dosisnedsættelse af neuroleptika, som metaboliseres af CYP3A eller CYP2D6, kan være nødvendig ved samtidig administration med EVOTAZ.
A decrease in the dose of neuroleptics metabolized by CYP3A or CYP2D6 may be required when co-administered with EVOTAZ.
Blandt de 19 patienter udviklede 1 den emtricitabine-relaterede resistenssubstitution M184V uden nogen resistenssubstitioner associeret med tenofovir eller proteasehæmmere.
Among the 19 patients, 1 developed the emtricitabine-associated resistance substitution M184V with no tenofovir or protease inhibitor associated resistance substitutions.
Sammenlignet med profilen for det enkelte lægemiddelstof kunne alle fund tilskrives enten atazanavir eller cobicistat.
When compared to their single-agent profiles all findings could be attributed to either atazanavir or cobicistat.
Samtidig administration med EVOTAZ kan øge plasmakoncentrationerne af lægemidler, der metaboliseres af CYP2D6 (se pkt.
Co-administration with EVOTAZ can increase plasma concentrations of medicinal products that are metabolised by CYP2D6 (see sections 4.3 and 4.5).
I et forsøg, hvor hiv-inficerede forsøgspersoner (n=22) blev instrueret i at tage atazanavir 300 mg med cobicistat 150 mg 1 gang dagligt med føde, var steady-state atazanavir Cmax, AUCtau and Ctau (gennemsnitlig ± SD) værdierne henholdsvis 3,9 ± 1,9 μg/ml, 46,1 ± 26,2 μg•hr/ml og 0,80 ± 0,72 μg/ml.
In a trial where HIV-infected subjects (n=22) were instructed to take atazanavir 300 mg with cobicistat 150 mg once daily with food, the steady-state atazanavir Cmax, AUCtau and Ctau (mean ± SD) values were 3.9 ± 1.9 μg/ml, 46.1 ± 26.2 μg•hr/ml and 0.80 ± 0.72 μg/ml, respectively.
Administration af en enkeltdosis EVOTAZ med et let måltid (336 kcal, 5,1 g fedt, 9,3 g protein) medførte en 42% stigning i atazanavir Cmax, en 28% stigning i atazanavir AUC, en 31% stigning i cobicistat Cmax og en 24% stigning i cobicistat AUC i forhold til fastende tilstand.
Administration of a single dose of EVOTAZ with a light meal (336 kcal, 5.1 g fat, 9.3 g protein) resulted in a 42% increase in atazanavir Cmax, a 28% increase in atazanavir AUC, a 31% increase in cobicistat Cmax, and a 24% increase in cobicistat AUC relative to the fasting state.
I en analyse af behandlingsnaive forsøgspersoner, som fik atazanavir 300 mg administreret sammen med cobicistat 150 mg i studie GS-US-216-0114 i uge 144, forelå der evaluerbare genotypiske data fra parvise baseline- og behandlingssvigt-isolater for alle 21 virologiske svigt i denne gruppe (6%, 21/344).
In an analysis of treatment-failure subjects who received atazanavir 300 mg co-administered with cobicistat 150 mg in study GS-US-216-0114 through Week 144, evaluable genotypic data from paired baseline and treatment-failure isolates were available for all 21 virologic failures in this group (6%, 21/344).
I det kliniske studie GS-US-216-0114, et fase 3 randomiseret, aktivt kontrolleret klinisk studie, hvor 692 behandlingsnaive patienter fik mindst en dosis atazanavir boostet med cobicistat (n = 344) eller atazanavir boostet med ritonavir (n = 348) administreret med andre antiretrovirale lægemidler, var de hyppigst rapporterede bivirkninger i gruppen med atazanavir boostet med cobicistat i et forløb på 144 uger associeret med forhøjede bilirubin-niveauer (se Tabel 2).
In clinical study GS-US-216-0114, a phase 3 randomised, active-controlled clinical study, in which 692 treatment-naïve patients received at least one dose of atazanavir boosted with cobicistat (n = 344) or atazanavir boosted with ritonavir (n = 348) administered with other antiretroviral medicinal products, the most frequently reported adverse reactions in the atazanavir boosted with cobicistat group during 144 weeks were associated with elevated bilirubin levels (see Table 2).
-2,2% (95% KI = -7,4%; 3,0%) -2,1% (95% KI = -8,7%; 4,5%)
Treatment difference -2.2% (95% CI = -7.4%, 3.0%) -2.1% (95% CI = -8.7%, 4.5%) Virologic failurec
Man bør udvise særlig forsigtighed, når EVOTAZ ordineres samtidig med lægemidler, som kan forøge QT-intervallet og/eller til patienter med allerede eksisterende risikofaktorer (bradykardi, medfødt langt QT, elektrolytforstyrrelser (se pkt.
Particular caution should be used when prescribing EVOTAZ in association with medicinal products which have the potential to increase the QT interval and/or in patients with pre-existing risk factors (bradycardia, long congenital QT, electrolyte imbalances (see sections 4.8 and 5.3).
Atazanavir med ritonavirf
Atazanavir with ritonavirf
Sildenafil, tadalafil og vardenafil metaboliseres af CYP3A4.
Sildenafil, tadalafil, and vardenafil are metabolised by CYP3A4.
Virologisk succes hiv-1 RNA <50 kopier/ml
HIV-1 RNA <50 copies/ml
Samtidig administration af voriconazol og EVOTAZ frarådes, medmindre en vurdering af fordele/risici berettiger brug af voriconazol (se pkt.
Co-administration of voriconazole and EVOTAZ is not recommended unless an assessment of the benefit/risk justifies the use of voriconazole (see section 4.5).
Clarithromycin kan øge koncentrationen af atazanavir og cobicistat.
Clarithromycin may increase concentrations of atazanavir and cobicistat.
HDPE-beholder (high density polyethylen) med børnesikret polypropylenlåg.
High density polyethylene (HDPE) bottle with a child-resistant polypropylene closure.
Efavirenz reducerer atazanavir-koncentrationen og forventes at nedsætte cobicistat-plasmakoncentrationerne.
Efavirenz decreases atazanavir concentrations and is expected to decrease cobicistat plasma concentrations.
Atazanavir har i kliniske studier vist sig at inducere dyslipidæmi i mindre udstrækning end andre sammenlignelige lægemiddelstoffer, der indgik i studierne.
In clinical studies, atazanavir has been shown to induce dyslipidaemia to a lesser extent than comparators.
Nogle patienter har oplevet svimmelhed, når de tager atazanavir eller cobicistat, som er de aktive stoffer i EVOTAZ.
Some patients have reported dizziness when taking atazanavir or cobicistat, active substances of EVOTAZ.
Samtidig administration af lægemidler, der er CYP3A-substrater og har et snævert terapeutisk indeks og med hvilke forhøjede plasmakoncentrationer associeres med alvorlige og/eller livstruende bivirkninger, er kontraindiceret sammen med EVOTAZ.
Co-administration of medicinal products that are substrates of CYP3A and have narrow therapeutic indeces and for which elevated plasma concentrations are associated with serious and/or life-threatening events are contraindicated with EVOTAZ.
Atazanavir og cobicistat metaboliseres via leveren.
Atazanavir and cobicistat are metabolised by the hepatic system.
Hud og subkutane væv almindelig udslæt ikke almindelig pruritus, erythema multiformea,b, toksiske huderuptionera,b, lægemiddelfremkaldt udslæt med eosinofili og systemiske symptomer (DRESS-syndrom)a,b, angiødema, urticaria, alopeci sjælden
Skin and subcutaneous tissue disorders common rash uncommon pruritus, erythema multiformea,b, toxic skin eruptionsa,b, drug rash with eosinophilia and systemic symptoms (DRESS) syndromea,b, angioedemaa, urticaria, alopecia rare
Samtidig administration af EVOTAZ og stavudin forventes ikke at påvirke stavudin-eksponeringen signifikant.
The co-administration of EVOTAZ with stavudine is not expected to significantly alter the exposure of stavudine.
Hjerte ikke almindelig torsades de pointesa sjælden
Cardiac disorders uncommon torsades de pointesa rare
Nervesystemet almindelig hovedpine, svimmelhed, døsighed, dysgeusi ikke almindelig perifer neuropati, synkope, amnesi
Nervous system disorders common headache, dizziness, somnolence, dysgeusia uncommon peripheral neuropathy, syncope, amnesia
Samtidig administration af EVOTAZ og disse lægemidler forventes at øge deres koncentrationer væsentligt og kan resultere i PDE5-relaterede bivirkninger såsom hypotension, synsforstyrrelser og priapisme (se pkt.
Co-administration of EVOTAZ with these medicinal products is expected to substantially increase their concentrations and may result in PDE5-associated adverse reactions such as hypotension, visual changes and priapism (see section 4.5).
Aktive stoffer: atazanavir og cobicistat.
The active substances are atazanavir and cobicistat.
Immunsystemet ikke almindelig overfølsomhed
Immune system disorders uncommon hypersensitivity
Klinisk monitorering anbefales ved samtidig administration af EVOTAZ, og dosisreducering af betablokkeren kan være nødvendig.
Clinical monitoring is recommended when co-administered with EVOTAZ and a dose reduction of the beta-blocker may be necessary.
Især atazanavir boostet med cobicistat er mere følsom over for CYP3A-induktion (se pkt.
In particular, atazanavir boosted with cobicistat is more sensitive for CYP3A induction (see section 4.3 and the interaction table).
Klinisk monitorering kan være nødvendig ved samtidig administration med EVOTAZ.
Clinical monitoring may be needed upon co-administration with EVOTAZ.
Det skal du vide, før du begynder at tage EVOTAZ
What you need to know before you take EVOTAZ
Middelændringen (± SD) i estimeret glomerulær filtrationsrate (eGFR) efter Cockcroft-Gault-metoden efter 144 ugers behandling var15,1 ± 16,5 ml/min i cobicistat-boostet atazanavir plus emtricitabin og tenofovir DF i fastdosiskombination-gruppen og -8,0 ± 16,8 ml/min i ritonavir-boostet atazanavir plus emtricitabin og tenofovir DF i fastdosiskombination-gruppen.
The mean (± SD) change in estimated glomerular filtration rate (eGFR) by Cockcroft-Gault method after 144 weeks of treatment was -15.1 ± 16.5 ml/min in the atazanavir boosted with cobicistat plus emtricitabine and tenofovir DF fixed-dose combination group and -8.0 ± 16.8 ml/min in the atazanavir boosted with ritonavir plus emtricitabine and tenofovir DF fixed-dose combination group.
EVOTAZ må ikke administreres sammen med colchicin til patienter med nedsat nyre- eller leverfunktion.
EVOTAZ must not be co-administered with colchicine to patients with renal or hepatic impairment.
Kontraindiceret på grund af den potentielle forøgelse i risiko for ALAT-stigninger grundet en signifikant stigning i plasmakoncentrationerne af glecaprevir og pibrentasvir (se pkt.
Contraindicated because of the potential increase in the risk of ALT elevations due to a significant increase in glecaprevir and pibrentasvir plasma concentrations (see section 4.3)
Resistensprofilen for EVOTAZ tilskrives atazanavir.
The resistance profile of EVOTAZ is driven by atazanavir.
Plasmakoncentrationerne for atazanavir kan nedsættes som følge af en reduktion af cobicistats plasmakoncentrationer, hvilket kan betyde tab af terapeutisk effekt og udvikling af resistens.
Atazanavir plasma concentrations may decrease as a consequence of a reduction in cobicistat plasma concentrations, which may result in loss of therapeutic effect and development of resistance.
Dyrestudier er utilstrækkelige med hensyn til reproduktionstoksicitet (se pkt.
Animal studies are insufficient with respect to reproductive toxicity (see section 5.3).
Klinisk monitorering af den terapeutiske effekt og bivirkninger anbefales, hvis disse lægemidler administreres samtidig med EVOTAZ.
Clinical monitoring of therapeutic effect and adverse events is recommended when these medicinal products are co-administered with EVOTAZ.
Eksponering for diltiazem og dets metabolit, desacetyl-diltiazem, øges ved samtidig administration af atazanavir, et af indholdsstofferne i EVOTAZ.
Exposure to diltiazem and a metabolite, desacetyl-diltiazem, is increased when diltiazem is co-administered with atazanavir, a component of EVOTAZ.
For lægemidler, der metaboliseres af CYP3A kan disse øgede plasmakoncentrationer potentielt medføre alvorlige, livstruende eller dødelige bivirkninger (se pkt.
For medicinal products metabolised by CYP3A these higher plasma concentrations may potentially lead to severe, life-threatening or fatal events (see sections 4.3 and 4.5).
Cobicistats effekt på atazanavirs farmakokinetik
Effect of cobicistat on atazanavir pharmacokinetics
kombinationsterapi med andre antiretrovirale lægemidler, hvor 1.806 voksne patienter fik atazanavir 400 mg 1 gang dagligt (1.151 patienter, 52 ugers median varighed og 152 ugers maksimal varighed) eller atazanavir 300 mg boostet med ritonavir 100 mg 1 gang dagligt (655 patienter, 96 ugers median varighed og 108 ugers maksimal varighed), var de hyppigst rapporterede bivirkninger kvalme, diarre og gulsot.
In 2 controlled clinical studies for combination therapy with other antiretroviral medicinal products 1,806 adult patients receiving atazanavir 400 mg once daily (1,151 patients, 52 weeks median duration and 152 weeks maximum duration) or atazanavir 300 mg boosted with ritonavir 100 mg once daily (655 patients, 96 weeks median duration and 108 weeks maximum duration), the most frequently reported adverse reactions were nausea, diarrhoea and jaundice.
Plasmakoncentrationerne af disse lægemidler kan øges ved samtidig administration af EVOTAZ, hvilket medfører nedsat serumkortisolkoncentrationer.
Plasma concentrations of these medicinal products may be increased when co-administered with EVOTAZ, resulting in reduced serum cortisol concentrations.
Itraconazol er i lighed med ketoconazol en potent CYP3A4-hæmmer og et CYP3A4-substrat.
Itraconazole, like ketoconazole, is a potent inhibitor as well as a substrate of CYP3A4.
Atazanavir må dog ikke anvendes hos patienter med moderat (Child-Pugh klasse B) til svært (Child-Pugh klasse C) nedsat leverfunktion.
However, atazanavir must not be used in patients with moderate (Child-Pugh Class B) to severe (Child-Pugh Class C) hepatic impairment.
Samtidig administration af EVOTAZ og warfarin kan potentielt medføre alvorlig og/eller livstruende blødning på grund af øgede plasmakoncentrationer af warfarin, og monitorering af INR (International Normalized Ratio) tilrådes (se pkt.
Co-administration of EVOTAZ with warfarin has the potential to produce serious and/or life-threatening bleeding due to increased warfarin plasma concentrations, and it is recommended that the INR (International Normalized Ratio) be monitored (see section 4.5).
Interaktionsmekanismen er CYP3A-induktion af antiepileptika.
The mechanism of interaction is CYP3A induction by the antiepileptic.
Der foreligger ingen farmakokinetiske data vedrørende anvendelse af EVOTAZ til patienter med nedsat leverfunktion.
There are no pharmacokinetic data regarding the use of EVOTAZ in patients with hepatic impairment.
AUC: ↔7% (↓11% ↓3%) Cmax: ↓13% (↓20% ↓6%) Cmin: Ikke bestemt
AUC: ↔7% (↓11% ↓3%) Cmax: ↓13% (↓20% ↓6%) Cmin: Not determined
Maraviroc forventes ikke at påvirke atazanavir- og cobicistat-koncentrationer.
Maraviroc is not expected to have an impact on concentrations of atazanavir and cobicistat.
Simeprevir kan øge atazanavir og/eller cobicistat plasmakoncentrationerne.
Simeprevir may increase atazanavir and/or cobicistat plasma concentrations.
Disse antiepileptika forventes at nedsætte atazanavirs og/eller cobicistats plasmakoncentrationer.
These antiepileptics are expected to decrease atazanavir and/or cobicistat plasma concentrations.
Atazanavir hæmmer UGT og kan interferere med irinotecanmetabolismen og medføre øget irinotecantoksicitet.
Atazanavir inhibits UGT and may interfere with the metabolism of irinotecan, resulting in increased irinotecan toxicities.
Vaskulære sygdomme ikke almindelig hypertension
Vascular disorders uncommon hypertension